Sanofi (Ablynx)

Technologiepark 21
9052 Zwijnaarde
BE
Sanofi (Ablynx)
Foundation date
13/07/2001
Sector
#Biotechnology - TherapeuticsSubsector
Therapeutic areas
- #Cardiovascular
- #Diseases of the blood and blood-forming organs - immune disorders
- #Diseases of the nervous system
- #Infectious and parasitic diseases
- #Musculoskeletal system and connective tissue
- #Neoplasms / cancer / oncology
- #Respiratory system
Sanofi R&D Belgium based in Ghent is as an end-to-end research and early development Center of Excellence and active in the discovery of NANOBODY® molecules, through the development of drugs up to their clinical proof-of-concept.
NANOBODY® molecules are proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® technology is the next generation of antibody-derived biologics and have great potential. They are being developed for the treatment of a range of serious and life-threatening human diseases including hematology, inflammation, immune-oncology, oncology and rare diseases.
Upcoming events
All events-
0106 '23
KNOWLEDGE FOR GROWTH 2023
Event by: flanders.bio -
0506 '23
BIO International Convention 2023
Event by: Biotechnology Innovation Organisation -
0604 '23
Innovation for Health 2023
Event by: Hyphen Projects
Latest news
More news-
Cerba Research & Teddy Lab sign Memorandum of Understanding on entering into a discussion for Joint Venture
7 hours ago
Read more
-
Novalis Biotech invests in Rarity Bioscience's ultra sensitive genomics technology
1 day ago
Read more
-
Fat creates an ideal environment for metastatic breast tumors
1 day ago
Read more
Jobs
More jobs-
07/02/23
Brussels
Postdoctoral position in cancer immunology and the tumor immune microenvironment
Permanent
VIB -
-